亚洲免费av电影一区二区三区,日韩爱爱视频,51精品视频一区二区三区,91视频爱爱,日韩欧美在线播放视频,中文字幕少妇AV,亚洲电影中文字幕,久久久久亚洲av成人网址,久久综合视频网站,国产在线不卡免费播放

        ?

        Hepatitis B core-related antigen: Are we near a treatment endpoint?

        2022-12-04 02:31:07TaranaGupta
        World Journal of Gastroenterology 2022年27期

        Tarana Gupta

        Abstract Different serological and virological markers in chronic hepatitis B patients guide staging of viral infection, and initiation and response to therapy. Due to the persistence of intrahepatic covalently closed circular DNA (cccDNA) in the hepatocyte nucleus, hepatitis B is not curable. Even after undetectable hepatitis B virus DNA levels, the persistence of hepatitis B surface antigen and novel markers such as hepatitis B core-related antigen (HBcrAg) indicate the persistence of intrahepatic cccDNA. In this study, HBcrAg levels at baseline and after 24 and 48 wk of antiviral therapy predicted hepatitis B e antigen seroconversion. Due to the poor sensitivity of assays and detectable levels in HBsAg-negative patients, the long-term utility of HBcrAg needs future research.

        Key Words: Hepatitis B core-related antigen; Chronic hepatitis B; Covalently closed circular DNA; Hepatitis B e antigen seroconversion; Hepatitis B virus DNA; Pregenomic RNA

        TO THE EDITOR

        We read with interest the study titled, “Serum hepatitis B core-related antigen as a surrogate marker of hepatitis B e antigen seroconversion in chronic hepatitis B” by Chiet al[1] in the World Journal of Gastroenterology. Hepatitis B core-related antigen (HBcrAg) and hepatitis B virus (HBV) RNA are potential serological markers of chronic hepatitis B infection and activity. In the HBV life cycle,intrahepatic covalently closed circular DNA (cccDNA) is transcribed into five RNAs of which pregenomic RNA is a precursor to synthesis of the viral genome by reverse transcription and precore mRNA is precursor to proteins hepatitis B core antigen. Hepatitis B e antigen (HBeAg) and p22cr are collectively called HBcrAg due to their identical 149 amino acid sequences. In addition, viral sequences also integrate in the host genome and can express hepatitis B surface antigen (HBsAg). Therefore,HBsAg quantification may not be exactly reflective of intrahepatic cccDNA levels. On the other hand,only cccDNA can express the viral genome. In real world settings, liver biopsy is not feasible for cccDNA quantification and a surrogate marker is needed in serum for intrahepatic cccDNA quantification. HBcrAg-related proteins can be detected in Dane particles, HBV DNA-negative Dane particles,and possibly in HBV RNA-containing virions[2]. Interestingly, nucleotide analogues (NAs) inhibit DNA polymerase and viral replication; they do not affect production of viral intermediate proteins such as HBcrAg. Therefore, even on antiviral treatment, HBcrAg can reflect cccDNA quantity and activity in hepatocytes.

        This study determined the predictive role of HBcrAg for HBeAg seroconversion in chronic hepatitis B(CHB) patients. All patients were analyzed for HBcrAg, HBV RNA, and HBV DNA levels in blood and cccDNA quantification in liver biopsy specimen. Although there is treatment heterogeneity with two different cohorts of entecavir (n= 109) and pegylated-interferon (PEG-IFN) (n= 30) therapy, the authors found baseline HBcrAg levels correlating with cccDNA levels in patients with and without HBeAg seroconversion. However, the PEG-IFN group only had 30 patients, and as IFNs are immunomodulators that increase innate immune response in controlling HBV infection with higher HBeAg seroconversion rates compared to NA therapy, it may be premature to conclude that it only affects viral replication and not the production of other viral proteins. Therefore, some bias may be related to treatment heterogeneity.

        This study also highlights that serum qHBcrAg levels at 24 and 48 wk of treatment better predict HBeAg seroconversion than qHBcrAg levels at baseline. Songet al[3] showed baseline HBcrAg levels <4.9 log U/mL, > 2 log reduction of HBcrAg at week 28 having a positive predictive value 74% and 76%,and negative predictive value of 96% and 94%, respectively, for the prediction of spontaneous HBeAg seroconversion. In HBeAg-positive CHB patients, HBcrAg is high in the immune tolerant phase compared to the immune clearance phase. And in HBeAg-negative patients, lower HBcrAg levels are present in the inactive carrier state than in HBeAg-negative CHB. Recently Ghanyet al[4] demonstrated a correlation of HBV RNA and HBcrAg levels with HBV DNA in different phases of CHB infection.

        Wonget al[5] demonstrated that correlation coefficients of serum HBV DNA and HBcrAg with intrahepatic cccDNA are 0.7 and 0.64-0.7, respectively, which are similar; however, in patients on antiviral therapy with undetectable serum HBV DNA, HBcrAg is the preferred marker for estimating intrahepatic cccDNA levels. Tsenget al[6] recently showed risk stratification of development of cirrhosis, and its complications and liver-related mortality in CHB patients over a period of 15.9 years by baseline HBcrAg levels. Careyet al[7] showed that HBcrAg and HBV RNA predict clinical flares in HBeAg-negative CHB patients with suppressed HBV DNA levels on nucleotide analogue therapy.Together, HBcrAg is a promising novel serum marker but with many limitations. First, with current available assays, the lower limit of detection is 2 log U/mL, so more sensitive assays are needed.Second, one study found detectable serum HBcrAg in 40% patients with HBsAg seroclearance[8].Finally, large-scale studies in different ethnic groups are needed to determine the predictive value of HBcrAg with certain cut-off values in clinical practice especially occult HBV reactivation, HBV flare after nucleotide analogue cessation, and risk of hepatocellular carcinoma development.

        FOOTNOTES

        Author contributions:Gupta T wrote and critically revised the manuscript.

        Conflict-of-interest statement:The author has no conflicts of interest to declare.

        Open-Access:This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BYNC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

        Country/Territory of origin:India

        ORCID number:Tarana Gupta 0000-0003-3453-2040.

        S-Editor:Wang JJ

        L-Editor:Filipodia

        P-Editor:Wang JJ

        少妇伦子伦精品无吗| 日本午夜剧场日本东京热| 亚洲丰满熟女乱一区二区三区 | 亚洲av网站在线免费观看| 亚洲一区二区婷婷久久| 中文字幕有码在线视频| 国产亚洲亚洲精品视频| 国产亚洲精品视频网站| 日韩在线精品视频一区| 激情人妻另类人妻伦| 久热re这里精品视频在线6| 亚洲av无码成人专区片在线观看 | 人妻一区二区三区免费看| 亚洲国产91高清在线| 国产精品久久久在线看| 日本熟妇人妻xxxx| 老师露出两个奶球让我吃奶头| 精品人妻va出轨中文字幕| 亚洲黄色电影| 亚洲AV毛片无码成人区httP| 久久99精品波多结衣一区| 亚洲av一区二区三区网站| 国产爽快片一区二区三区| 少妇被黑人整得嗷嗷叫视频 | 人妻av鲁丝一区二区三区| 精品爆乳一区二区三区无码av| 亚洲av无码片在线播放| 亚洲av毛片一区二区久久| 五月激情在线视频观看| 国模无码一区二区三区| 大伊香蕉在线精品视频75| 国产成人77亚洲精品www| 国产精品欧美视频另类专区| 国产精品高清一区二区三区人妖| 国产高清精品一区二区| 大地资源在线影视播放| 中文字幕久久精品一二三区| 日本午夜国产精彩| 性感人妻一区二区三区| 女同av一区二区三区| 亚洲愉拍99热成人精品热久久|